Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNTO 888 + doxorubicin liposomal
- Development stage
- Preclinical
- Lead developer
- Janssen Pharmaceutical
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CNTO 888 + doxorubicin liposomal is a combination of two investigational/therapeutic agents. **CNTO 888** is a human monoclonal antibody targeting C-C motif chemokine ligand 2 (CCL2, also known as monocyte chemoattractant protein-1/MCP-1). It is being investigated as an immunotherapy agent that may inhibit tumor-associated macrophage recruitment and angiogenesis by neutralizing CCL2. **Doxorubicin liposomal** is an anthracycline chemotherapeutic agent encapsulated in pegylated liposomes to improve tumor delivery and reduce toxicity, blocking topoisomerase II, resulting in DNA damage and apoptosis preferentially in rapidly dividing cells. The combination is investigated in oncology, seeking to leverage CNTO 888’s immunomodulatory effect with the cytotoxic action of liposomal doxorubicin.
- Brand names
- Lipodox
- Other names
- doxorubicin HCl liposomepegylated liposomal doxorubicinDoxilDLIhuman anti-CCL2 antibody (for CNTO 888)
02
Targets
DNACCL2 (C-C motif chemokine 2)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on CNTO 888 + doxorubicin liposomal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNTO 888 + doxorubicin liposomal.